---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-029050"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2024-06-06T23:59:59+00:00"
generated_at: "2026-06-01T05:57:24.668997+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BridgeBio reports positive Phase 2 infigratinib results in achondroplasia; initiates hypochondroplasia study

## Summary
- Cohort 5 (0.25 mg/kg/day) showed sustained AHV increase: +2.51 cm/yr at Month 12, +2.50 cm/yr at Month 18 (p=0.0015).
- Statistically significant improvement in body proportionality: upper/lower segment ratio 1.88 at Month 18 vs 2.02 baseline (p=0.001).
- No treatment-related adverse events in Cohort 5; drug well-tolerated as single daily oral therapy.
- First child consented in ACCEL observational study for hypochondroplasia; Phase 2/3 interventional study planned.
- PROPEL 3 Phase 3 registrational enrollment on schedule, completion estimated by end of 2024.

## SEC filing metadata
- accession: 0001140361-24-029050
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2024-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036124029050/0001140361-24-029050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036124029050/ef20030678_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-029050
- JSON: https://secwatch.observer/filing/0001140361-24-029050.json
- Plain text: https://secwatch.observer/filing/0001140361-24-029050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.